ARWR vs EHC: Which Stock Is the Better Buy?
Arrowhead Pharmaceuticals, Inc. and Encompass Health Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARWR vs EHC, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Encompass Health Corporation (EHC) | |
|---|---|---|
| Market cap | $10.0B | $10.1B |
| Revenue (latest FY) | $829.45M | $5.94B |
| Net income (latest FY) | $-1.63M | $566.20M |
| Revenue growth (5y CAGR) | 56.6% | 10.7% |
| Net margin | -0.2% | 9.5% |
| Return on equity | -0.3% | 23.2% |
| P/E ratio | — | 17.5 |
| Dividend yield | — | 0.7% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ARWR vs EHC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARWR's full financials → Open EHC's full financials →More comparisons
Frequently asked questions
Which is bigger, ARWR or EHC?
Encompass Health Corporation is larger by market capitalization — $10.1B versus $10.0B.
Which grows faster, ARWR or EHC?
Over the last five fiscal years, Arrowhead Pharmaceuticals, Inc. grew revenue faster — 56.6%/yr versus 10.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.